Correct Answer: B. Flow cytometry of peripheral blood
In chronic lymphocytic leukemia (CLL), the diagnosis is established by demonstrating absolute lymphocytosis >5,000/µL sustained for ≥3 months, which this patient clearly has (35,000/µL). Flow cytometry of peripheral blood is the gold standard for both confirming CLL and characterizing the immunophenotype. CLL is defined by a clonal population of CD5+ B lymphocytes (co-expressing CD19, CD20, and CD23), and flow cytometry directly identifies these CD markers in circulating cells. The test is rapid, minimally invasive, cost-effective, and provides definitive immunophenotypic data (CD5+, CD19+, CD20+, CD23+, surface immunoglobulin+) that distinguishes CLL from other lymphoproliferative disorders like mantle cell lymphoma (CD5+, CD23−) or marginal zone lymphoma. In the Indian context, where CLL accounts for ~30% of adult leukemias, flow cytometry is the standard first-line confirmatory test recommended by Indian hematology guidelines. The test also helps stage disease and predict prognosis (e.g., del(17p) or TP53 mutation detection in advanced flow panels).
Why the other options are wrong
A. Lymph node excisional biopsy — While lymph node biopsy can confirm lymphoid malignancy histologically, it is invasive, time-consuming, and unnecessary when CLL is already suspected with marked lymphocytosis. Flow cytometry provides faster, definitive immunophenotyping without surgical morbidity. Biopsy is reserved for cases where flow cytometry is inconclusive or when tissue architecture assessment is needed (e.g., Richter transformation). C. Bone marrow biopsy — Bone marrow biopsy is not required for CLL diagnosis; it is invasive and painful. While marrow involvement may be assessed for staging, the diagnosis and CD marker characterization are definitively established by peripheral blood flow cytometry alone. Marrow biopsy is reserved for specific indications like cytopenias or suspected Richter transformation. D. Serum LDH levels — Serum LDH is a prognostic marker in CLL (elevated LDH indicates aggressive disease), but it does NOT confirm diagnosis or determine CD markers. LDH is non-specific and cannot differentiate CLL from other malignancies. It is a supportive test used alongside flow cytometry for risk stratification, not for diagnostic confirmation.
High-Yield Facts
- CLL diagnosis requires absolute lymphocyte count >5,000/µL for ≥3 months plus clonality confirmed by flow cytometry.
- CD5+ B-cell phenotype (CD5, CD19, CD20, CD23, surface Ig+) is the hallmark of CLL and is identified only by flow cytometry.
- Flow cytometry is the gold standard for CLL confirmation and immunophenotyping; it is rapid, non-invasive, and cost-effective.
- Mantle cell lymphoma (CD5+, CD23−) and marginal zone lymphoma (CD5−, CD23−) are distinguished from CLL by flow cytometry CD marker patterns.
- Prognostic markers in CLL (del(17p), TP53 mutation, elevated LDH) are detected by advanced flow cytometry or molecular testing, not by biopsy.
Mnemonics
CLL Diagnosis: FAB (Flow, Absolute count, B-cell markers) Flow cytometry confirms diagnosis and CD markers → Absolute lymphocytosis >5,000/µL → B-cell phenotype (CD5+, CD19+, CD20+, CD23+). Use this when deciding between biopsy and flow cytometry. CD5+ Lymphomas: MCCL (Mantle Cell, CLL, Lymphoplasmacytic) CD5+ B-cell malignancies include Mantle Cell (CD23−), CLL (CD23+), and Lymphoplasmacytic. Flow cytometry differentiates them by CD23 and other markers. Helps rule out mimics when flow shows CD5+.
NBE Trap
NBE may lure students into choosing lymph node biopsy by emphasizing "confirm diagnosis" — but the question specifically asks for the investigation that determines CD markers, which only flow cytometry provides. Biopsy shows histology, not immunophenotype.
Clinical Pearl
In Indian tertiary centers, flow cytometry is now widely available and has replaced bone marrow examination as the first-line test for suspected CLL. A patient with lymphocytosis and generalized lymphadenopathy should have peripheral blood flow cytometry ordered immediately; if positive for CD5+ B-cell clonality, CLL is confirmed without need for invasive biopsy.
_Reference: Robbins Ch. 13 (Hematopoietic and Lymphoid Neoplasms); Harrison Ch. 104 (Chronic Lymphoid Leukemias)_